Tevogen Bio (TVGN) Competitors

Tevogen Bio logo
$5.69 -0.53 (-8.52%)
Closing price 11/17/2026 03:53 PM Eastern
Extended Trading
$5.74 +0.04 (+0.79%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TVGN vs. CMPX, MGNX, AKBA, CUE, and PRQR

Should you buy Tevogen Bio stock or one of its competitors? Tevogen Bio's main competitors and comparable companies include Compass Therapeutics (CMPX), MacroGenics (MGNX), Akebia Therapeutics (AKBA), Cue Biopharma (CUE), and ProQR Therapeutics (PRQR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tevogen Bio compare to Compass Therapeutics?

Tevogen Bio (NASDAQ:TVGN) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Tevogen Bio and Tevogen Bio both had 2 articles in the media. Tevogen Bio's average media sentiment score of 1.61 beat Compass Therapeutics' score of -0.22 indicating that Tevogen Bio is being referred to more favorably in the media.

Company Overall Sentiment
Tevogen Bio Very Positive
Compass Therapeutics Neutral

Tevogen Bio's return on equity of 0.00% beat Compass Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tevogen BioN/A N/A -495.15%
Compass Therapeutics N/A -49.93%-43.76%

Tevogen Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Compass Therapeutics has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 1,657.47%. Compass Therapeutics has a consensus target price of $9.99, indicating a potential upside of 1,546.89%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Compass Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Compass Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.76

68.4% of Compass Therapeutics shares are held by institutional investors. 65.6% of Tevogen Bio shares are held by company insiders. Comparatively, 18.7% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tevogen Bio has higher earnings, but lower revenue than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tevogen BioN/AN/A-$26.27M-$4.63N/A
Compass Therapeutics$850K128.54-$66.49M-$0.47N/A

Summary

Compass Therapeutics beats Tevogen Bio on 8 of the 13 factors compared between the two stocks.

How does Tevogen Bio compare to MacroGenics?

Tevogen Bio (NASDAQ:TVGN) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Tevogen Bio has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. Tevogen Bio's return on equity of 0.00% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tevogen BioN/A N/A -495.15%
MacroGenics -45.37%-246.62%-31.36%

96.9% of MacroGenics shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tevogen Bio has higher earnings, but lower revenue than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tevogen BioN/AN/A-$26.27M-$4.63N/A
MacroGenics$149.50M0.88-$74.62M-$0.81N/A

Tevogen Bio has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

In the previous week, MacroGenics had 6 more articles in the media than Tevogen Bio. MarketBeat recorded 8 mentions for MacroGenics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.61 beat MacroGenics' score of 0.03 indicating that Tevogen Bio is being referred to more favorably in the media.

Company Overall Sentiment
Tevogen Bio Very Positive
MacroGenics Neutral

Tevogen Bio presently has a consensus price target of $100.00, indicating a potential upside of 1,657.47%. MacroGenics has a consensus price target of $8.50, indicating a potential upside of 314.63%. Given Tevogen Bio's higher possible upside, equities research analysts plainly believe Tevogen Bio is more favorable than MacroGenics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

MacroGenics beats Tevogen Bio on 8 of the 14 factors compared between the two stocks.

How does Tevogen Bio compare to Akebia Therapeutics?

Tevogen Bio (NASDAQ:TVGN) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Tevogen Bio currently has a consensus target price of $100.00, suggesting a potential upside of 1,657.47%. Akebia Therapeutics has a consensus target price of $3.50, suggesting a potential upside of 774.13%. Given Tevogen Bio's higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than Akebia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Akebia Therapeutics
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.43

Akebia Therapeutics has higher revenue and earnings than Tevogen Bio. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tevogen BioN/AN/A-$26.27M-$4.63N/A
Akebia Therapeutics$236.20M0.47-$5.34M-$0.16N/A

In the previous week, Akebia Therapeutics had 7 more articles in the media than Tevogen Bio. MarketBeat recorded 9 mentions for Akebia Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.61 beat Akebia Therapeutics' score of -0.19 indicating that Tevogen Bio is being referred to more favorably in the media.

Company Overall Sentiment
Tevogen Bio Very Positive
Akebia Therapeutics Neutral

33.9% of Akebia Therapeutics shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tevogen Bio has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -22.60%. Tevogen Bio's return on equity of 0.00% beat Akebia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tevogen BioN/A N/A -495.15%
Akebia Therapeutics -22.60%-156.59%-11.53%

Tevogen Bio has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Summary

Akebia Therapeutics beats Tevogen Bio on 9 of the 14 factors compared between the two stocks.

How does Tevogen Bio compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

35.0% of Cue Biopharma shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cue Biopharma had 7 more articles in the media than Tevogen Bio. MarketBeat recorded 9 mentions for Cue Biopharma and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.61 beat Cue Biopharma's score of 0.07 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Cue Biopharma Neutral
Tevogen Bio Very Positive

Tevogen Bio has lower revenue, but higher earnings than Cue Biopharma. Tevogen Bio is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$27.47M0.75-$26.60M-$27.02N/A
Tevogen BioN/AN/A-$26.27M-$4.63N/A

Cue Biopharma presently has a consensus target price of $83.00, indicating a potential upside of 2,832.86%. Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,657.47%. Given Cue Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Cue Biopharma is more favorable than Tevogen Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Cue Biopharma has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Tevogen Bio has a net margin of 0.00% compared to Cue Biopharma's net margin of -579.95%. Tevogen Bio's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-579.95% -820.77% -398.14%
Tevogen Bio N/A N/A -495.15%

Summary

Cue Biopharma beats Tevogen Bio on 8 of the 14 factors compared between the two stocks.

How does Tevogen Bio compare to ProQR Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

ProQR Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 11 more articles in the media than Tevogen Bio. MarketBeat recorded 13 mentions for ProQR Therapeutics and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.61 beat ProQR Therapeutics' score of 0.76 indicating that Tevogen Bio is being referred to more favorably in the news media.

Company Overall Sentiment
ProQR Therapeutics Positive
Tevogen Bio Very Positive

Tevogen Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -205.68%. Tevogen Bio's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-205.68% -72.78% -36.77%
Tevogen Bio N/A N/A -495.15%

32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 65.6% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tevogen Bio has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Tevogen Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$17.99M6.74-$47.73M-$0.46N/A
Tevogen BioN/AN/A-$26.27M-$4.63N/A

ProQR Therapeutics currently has a consensus price target of $7.60, indicating a potential upside of 560.87%. Tevogen Bio has a consensus price target of $100.00, indicating a potential upside of 1,657.47%. Given Tevogen Bio's higher probable upside, analysts plainly believe Tevogen Bio is more favorable than ProQR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Tevogen Bio
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

ProQR Therapeutics beats Tevogen Bio on 9 of the 15 factors compared between the two stocks.

Get Tevogen Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVGN vs. The Competition

MetricTevogen BioBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$40.50M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7134.3428.32
Price / SalesN/A15.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-0.034.184.453.72
Net Income-$26.27M-$24.15M$3.52B$393.10M
7 Day Performance0.62%-7.81%-5.93%-5.77%
1 Month Performance-17.72%-5.99%-4.58%-7.14%
1 Year Performance-72.18%-8.09%-1.94%-7.46%

Tevogen Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVGN
Tevogen Bio
2.8688 of 5 stars
$5.69
-8.5%
$100.00
+1,657.5%
-70.6%$40.50MN/AN/A18
CMPX
Compass Therapeutics
3.4998 of 5 stars
$0.84
+0.1%
$9.99
+1,092.3%
-87.6%$150.72M$850KN/A39
MGNX
MacroGenics
2.5567 of 5 stars
$2.42
+3.4%
$8.50
+251.2%
+35.8%$149.06M$149.50MN/A293
AKBA
Akebia Therapeutics
2.2013 of 5 stars
$0.54
+1.7%
$3.90
+619.8%
-77.3%$147.94M$236.20MN/A194
CUE
Cue Biopharma
2.7761 of 5 stars
$18.76
-6.9%
$83.00
+342.4%
-99.5%$146.30M$27.47MN/A29

Related Companies and Tools


This page (NASDAQ:TVGN) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners